Trilobio, developer of whole lab automation solutions for advancing biology research, today introduced the first version of its comprehensive robotics, lab equipment and software platform at the Society for Laboratory Automation and Screening conference, SLAS2025, alongside pilot customer data, demonstrating the platform’s abilities in advancing research workflows.
Trial finds no benefit of adding nivolumab to tivozanib for advanced kidney cancer
In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab
September 13, 2024